6-chloro-4-phenylpyridazin-3-amine | 944468-99-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-chloro-4-phenylpyridazin-3-amine
• 英文别名: 6-chloro-4-phenylpyridazin-3-ylamine；6-Chloro-4-phenylpyridazin-3-amine
• CAS: 944468-99-9
• 化学式: C₁₀H₈ClN₃
• 分子量: 205.647
• InChiKey: UXKMIHDDECVHGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-chloro-4-phenylpyridazin-3-amine 在 氢碘酸 作用下， 以 水 为溶剂， 以94%的产率得到
  参考文献：
  名称：

  Facile synthesis of 4-aryl and alkyl substituted, N 6 -alkylated pyridazine-3,6-diamines

  摘要：

  Substituted pyridazine-3,6-diamines are attractive but poorly precedented scaffolds in medicinal chemistry and are challenging targets in terms of synthetic tractability. In the following communication we report the use of a Buchwald protocol for the facile synthesis of 4-aryl and alkyl substituted, N-6-alkylated pyridazine-3,6-diamines. This approach utilises the unreactive nature of the pyridazine 3-amino group, negating the need for an additional protecting group in the transformation. The relevant precursors were prepared by selective Suzuki or Negishi transformations using commercially available 4-bromo-6-chloro-3-pyridazinamine. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2015.10.075
• 作为产物：
  描述：

  苯基顺酐 在 ammonium hydroxide 、 硫酸肼 、 三氯氧磷 作用下， 以 水 为溶剂， 生成 6-chloro-4-phenylpyridazin-3-amine
  参考文献：
  名称：

  Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors

  摘要：

  The design and synthesis of pyridazinone and phthalazinone derivatives are described. Newly synthesized compounds were tested on a panel of four kinases in order to evaluate their activity and potential selectivity. In addition, the promising compounds were tested on four cancer cell lines to examine cytotoxic effects. The compounds inhibited DYRK1A and GSK3 with different activity. SAR analysis and docking calculations were carried out to aid in the interpretation of the results. Taken together, our findings suggest that pyridazinone and phthalazinone scaffolds are interesting starting points for design of potent GSK3 and DYRK1A inhibitors. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.027

文献信息

• [EN] THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES DE PYRIDAZINE ET LEURS UTILISATIONS
  申请人：GENENTECH INC

  公开号：WO2016138114A1

  公开（公告）日：2016-09-01

  The present invention relates to compounds of formula (I): (I) and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.

  本发明涉及式(I)的化合物及其盐，其中：R1-R4具有规范中定义的任何值，以及其组合物和用途。这些化合物可用作BRG1、BRM和/或PB1的抑制剂。还包括包含式(I)的化合物或其药学上可接受的盐的药物组合物，以及在治疗各种BRG1介导的疾病、BRM介导的疾病和/或PB1介导的疾病中使用这些化合物和盐的方法。
• 1,2-PYRIDAZINES, 1,6-PYRIDAZINES AND PYRIMIDINES
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20130267519A1

  公开（公告）日：2013-10-10

  This invention relates to novel 1,2-pyridazines, 1,6-pyridazines or pyrimidines of the formula wherein B 1 to B 3 and R 1 to R 7 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and may therefore be useful as medicaments for the treatment of diseases such as type II diabetes.

  本发明涉及新颖的1,2-吡啶嗪、1,6-吡啶嗪或嘧啶的化合物，其化学式如下，其中B1至B3和R1至R7如描述和索赔中所定义，并且其药学上可接受的盐。这些化合物是GPBAR1激动剂，因此可能用作治疗疾病如2型糖尿病的药物。
• SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES
  申请人：Rehwinkel Hartmut

  公开号：US20130210825A1

  公开（公告）日：2013-08-15

  The invention relates to imidazo[1,2-b]pyridazines of general formula (I) a process for their manufacuture and their use for the treatment of benign and malignant neoplasia.

  该发明涉及通式（I）的咪唑并[1,2-b]吡啶嗪化合物，以及其制备方法和用于治疗良性和恶性肿瘤的用途。
• [EN] 1,2- PYRIDAZINE, 1,6- PYRIDAZINE OR PYRIMIDINE - BENZAMIDE DERIVATIVES AS GPBAR1 MODULATORS<br/>[FR] DÉRIVÉS DE 1,2-PYRIDAZINE, 1,6-PYRIDAZINE OU PYRIMIDINE-BENZAMIDE COMME MODULATEURS DE GPBAR1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013149977A1

  公开（公告）日：2013-10-10

  This invention relates to novel 1,2-pyridazines, 1,6-pyridazines or pyrimidines of the formula I wherein B1 to B3 and R1 to R7 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and may therefore be useful as medicaments for the treatment of diseases such as type II diabetes.

  本发明涉及新颖的1,2-吡啶嗪、1,6-吡啶嗪或式I中的嘧啶，其中B1至B3和R1至R7如描述和权利要求中所定义，并且其药学上可接受的盐。这些化合物是GPBAR1激动剂，因此可能用作治疗疾病如2型糖尿病的药物。
• Substituted imidazo[1,2-B]pyridazines
  申请人：Rehwinkel Hartmut

  公开号：US08987273B2

  公开（公告）日：2015-03-24

  The invention relates to imidazo[1,2-b]pyridazines of general formula (I) a process for their manufacture and their use for the treatment of benign and malignant neoplasia.

  本发明涉及一般式（I）的咪唑并[1,2-b]吡嗪类化合物的制备方法以及它们用于治疗良性和恶性肿瘤的用途。